ClouDr Group (9955) Fair Value & Analysis
Healthcare · HK · Market cap HK$349M
Fair value as of: Jul 3, 2026
From 1 valuation models · updated 21 days ago
Share price −3.8% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$0.5100 – HK$1.77 · fair‑value band HK$0.4900 – HK$0.9800 · the HK$0.5100 price screens below the HK$0.6600 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ClouDr Group (9955) currently trades at HK$0.5100, while our model-based Fair Value estimate is HK$0.6600, implying the stock looks roughly 29.4% undervalued today. We read business quality at 26/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, ClouDr Group generated revenue of HK$1.6B at a net margin of -56.9%. Revenue declined 46.4% year over year. The balance sheet holds a net cash position of HK$18.0M. Fundamentals as of Jul 3, 2026
Our scenario range runs from HK$0.4900 (bear case) to HK$0.9800 (bull case); at HK$0.5100, the current price sits within that range. The share trades about 72% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 29%, 9955 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) installation to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for patients with chronic condition management. The company's integrated in-hospital solution offers an AI-driven extensive hospital SaaS to assist doctors in diagnosis and treatment, and to help enhance the doctor education; chronic condition management solution to hospitals, including hospital SaaS and proprietary artificial intelligence of things devices. It also offers pharmacy SaaS, which enables in-store, real-time online consultation, prescription, and risk pooling of outpatient services; and sells chronic condition related drugs based on its data insights in pharmacies, including information on inventory, sales, and shipments of prescription drugs. In addition, the company provides integrated in-and out-of-hospital solutions that …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ClouDr Group reported revenue of HK$1.6B in FY2025 versus HK$1.8B in FY2021, a compound −2.0%/yr. Reported net income was −HK$924M in FY2025.
Is 9955 fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc COR | $281.24 | $168.24 | -40% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Henry Schein, Inc HSIC | $78.67 | $67.77 | -14% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥20.81 | ¥25.18 | +21% |
| Medipal Holdings MEPDF | $18.35 | $23.62 | +29% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ClouDr Group (9955) undervalued?
What is the fair value of 9955?
What is the quality score of 9955?
What is the revenue of ClouDr Group (9955)?
What is the net profit margin of 9955?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full ClouDr Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.